AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017
- By insider
AtriCure Inc (ATRC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. AtriCure Inc has a market cap of $609.140 million; its shares were traded at around $17.67 with and P/S ratio of 3.35. AtriCure Inc had annual average EBITDA growth of 32.10% over the past five years.
Warning! GuruFocus has detected 1 Warning Sign with ATRC. Click here to check it out.
The intrinsic value of ATRC
For the last quarter AtriCure Inc reported a revenue of $42.2 million, compared with the revenue of $38.34 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $174.7 million, an increase of 12.6% from last year. For the last five years AtriCure Inc had an average revenue growth rate of 21% a year.
The reported loss per diluted share was 83 cents for the year, compared with the loss per share of $0.56 in the previous year. The AtriCure Inc had an operating margin of -14.3%, compared with the operating margin of -20.07% a year before. The 10-year historical median operating margin of AtriCure Inc is -17.57%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, AtriCure Inc has the cash and cash equivalents of $34.5 million, compared with $24.2 million in the previous year. The long term debt was $36.9 million, compared with $37.2 million in the previous year. The interest coverage to the debt is at a comfortable level of 963.3. AtriCure Inc has a financial strength rank of 6 (out of 10).
At the current stock price of $17.67, AtriCure Inc is traded at 11.2% premium to its historical median P/S valuation band of $15.89. The P/S ratio of the stock is 3.35, while the historical median P/S ratio is 3.01. The stock lost 3.18% during the past 12 months.
Directors and Officers Recent Trades:
SVP, Mktg & Business Develop Justin J Noznesky sold 4,000 shares of ATRC stock on 02/15/2018 at the average price of $17.03. The price of the stock has increased by 3.76% since.
For the complete 20-year historical financial data of ATRC, click here.
This article first appeared on GuruFocus.
Warning! GuruFocus has detected 1 Warning Sign with ATRC. Click here to check it out.
The intrinsic value of ATRC
